Carlo Adornetto

Mr. Carlo Adornetto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
FMFortunato Morabito
Fortunato Morabito
CACarlo Adornetto
Carlo Adornetto
PMPaola Monti
Paola Monti
AAAdriana Amaro
Adriana Amaro
FRFrancesco Reggiani
Francesco Reggiani
GGGianluigi Greco
Gianluigi Greco
Analyzing gene expression profiles (GEP) through artificial intelligence provides meaningful insight into cancer disease. This study introduces DeepSHAP Autoencoder Filter for Genes Selection (DSAF-GS), a novel deep learning and explainable artificial intelligence-based approach for feature selection in genomics-scale data. DSAF-GS exploits the autoencoder’s reconstruction capabilities without changing the original feature space, enhancing the interpretation of the results. Explainable artificial intelligence is then used to select the informative genes for chronic lymphocytic leukemia prognosis of 217 cases from a GEP database comprising roughly 20,000 genes. The model for prognosis prediction achieved an accuracy of 86.4%, a sensitivity of 85.0%, and a specificity of 87.5%. According to the proposed approach, predictions were strongly influenced by CEACAM19 and PIGP, moderately influenced by MKL1 and GNE, and poorly influenced by other genes. The 10 most influential genes were selected for further analysis. Among them, FADD, FIBP, FIBP, GNE, IGF1R, MKL1, PIGP, and SLC39A6 were identified in the Reactome pathway database as involved in signal transduction, transcription, protein metabolism, immune system, cell cycle, and apoptosis. Moreover, according to the network model of the 3D protein-protein interaction (PPI) explored using the NetworkAnalyst tool, FADD, FIBP, IGF1R, QTRT1, GNE, SLC39A6, and MKL1 appear coupled into a complex network. Finally, all 10 selected genes showed a predictive power on time to first treatment (TTFT) in univariate analyses on a basic prognostic model including IGHV mutational status, del(11q) and del(17p), NOTCH1 mutations, β2-microglobulin, Rai stage, and B-lymphocytosis known to predict TTFT in CLL. However, only IGF1R [hazard ratio (HR) 1.41, 95% CI 1.08-1.84, P=0.013), COL28A1 (HR 0.32, 95% CI 0.10-0.97, P=0.045), and QTRT1 (HR 7.73, 95% CI 2.48-24.04, P<0.001) genes were significantly associated with TTFT in multivariable analyses when combined with the prognostic factors of the basic model, ultimately increasing the Harrell’s c-index and the explained variation to 78.6% (versus 76.5% of the basic prognostic model) and 52.6% (versus 42.2% of the basic prognostic model), respectively. Also, the goodness of model fit was enhanced (χ2 = 20.1, P=0.002), indicating its improved performance above the basic prognostic model. In conclusion, DSAF-GS identified a group of significant genes for CLL prognosis, suggesting future directions for bio-molecular research.

5 May 2025 in IEEE Transactions on Artificial Intelligence
Verified
Journal Article
Open access
CACarlo Adornetto
Carlo Adornetto
AMAdrian Mora
Adrian Mora
KHKai Hu
Kai Hu
LGLeticia Izquierdo Garcia
Leticia Izquierdo Garcia
parfait atchadéparfait atchadé
parfait atchadé
KLKent Larson
Kent Larson
The advent of Generative Agents (GAs) based on Large Language Models (LLMs) has significantly influenced the evolution of Agent-Based Modeling (ABM), offering new perspectives across various domains, including engineering and social sciences. This paper provides an extensive overview of the integration of GAs into ABMs, emphasizing the advancements and emerging challenges in their validation. Traditional ABMs, characterized by their simplistic yet powerful approach to modeling complex systems, have been redefined with the introduction of GAs. This new generation of agents is often equipped with conversational capabilities. These agents, capable of simulating believable human behaviors and interactions, present unique opportunities and hurdles, especially in urban simulations and social dynamics. We explore the nuanced differences between traditional ABMs and ABMs populated by GAs—called GABMs. We delve into the state-of-the-art implementations of GAs, and review various validation methods. Through this comprehensive examination, we aim to shed light on the potential and limitations of GAs, advocating for the design of hybrid ABM-GABM approaches and systematic validation.

15 December 2024 in European Journal of Innovation Management
Verified
Journal Article
Open access
PDF file
FFFrancesco Fasano
Francesco Fasano
CACarlo Adornetto
Carlo Adornetto
IZIliess Zahid
Iliess Zahid
MRMaurizio La Rocca
Maurizio La Rocca
LMLuigi Montaleone
Luigi Montaleone
ACalfio cariola
alfio cariola
Purpose: Our aim is to develop a highly precise corporate crisis prediction model that surpasses previous versions, rooted in the forefront of technological advancements. Design/methodology/approach: Artificial Intelligence (AI) for corporate default prediction with a novel approach based on a mix of techniques, enabling it to achieve a higher accuracy. We investigated models with sequence lengths that were both fixed and variable, and we chose the best variable sequence length model. Findings: Our findings demonstrate that the artificial techniques implemented lead to very high accuracy in predicting business crises compared to previous research efforts, even those utilising long-time sequences or a high volume of observations. Research limitations/implications: We highlight the key variables with a higher predictive power that need monitoring to prevent business crises. We also aim to open a new avenue of research that, starting from the use of these techniques and our results, can implement models incorporating non-accounting variables to prevent business crises. Practical implications: We provide a model/tool that assesses a possible business crisis in advance through a monitoring and alert system. Policymakers can use our research’s output as a tool to combine with current credit-scoring systems and to assess the effectiveness of the new corporate crisis reforms that are upcoming in many European countries. The results of our research can be useful also to banks, public entities, and consulting firms that interact with companies and are interested in the evaluation of a firm’s financial health and stability. Originality/value: Our innovative work leverages cutting-edge methodologies such as deep Recurrent Neural Networks and explainable AI. This choice is driven by the rapid evolution of AI techniques in practical application.

23 August 2024 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
ENEnnio Nano
Ennio Nano
FRFrancesco Reggiani
Francesco Reggiani
AAAdriana Agnese Amaro
Adriana Agnese Amaro
PMPaola Monti
Paola Monti
MCMonica Colombo
Monica Colombo
Giovanna CutronaGiovanna Cutrona
Giovanna Cutrona
A “watch and wait” strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study, six well-established variables (i.e., Rai stage, beta-2-microglobulin levels, IGVH mutational status, del11q, del17p, and NOTCH1 mutations) maintained significant associations with TTFT in a basic multivariable model, collectively yielding a Harrell’s C-index of 75% and explaining 45.4% of the variance in the prediction of TTFT. Concerning miRNAs, 73 out of 513 were significantly associated with TTFT in a univariable model; of these, 16 retained an independent relationship with the outcome in a multivariable analysis. For 8 of these (i.e., miR-582-3p, miR-33a-3p, miR-516a-5p, miR-99a-5p, and miR-296-3p, miR-502-5p, miR-625-5p, and miR-29c-3p), a lower expression correlated with a shorter TTFT, whereas in the remaining eight (i.e., miR-150-5p, miR-148a-3p, miR-28-5p, miR-144-5p, miR-671-5p, miR-1-3p, miR-193a-3p, and miR-124-3p), the higher expression was associated with shorter TTFT. Integrating these miRNAs into the basic model significantly enhanced predictive accuracy, raising the Harrell’s C-index to 81.1% and the explained variation in TTFT to 63.3%. Moreover, the inclusion of the miRNA scores enhanced the integrated discrimination improvement (IDI) and the net reclassification index (NRI), underscoring the potential of miRNAs to refine CLL prognostic models and providing insights for clinical decision-making. In silico analyses on the differently expressed miRNAs revealed their potential regulatory functions of several pathways, including those involved in the therapeutic responses. To add a biological context to the clinical evidence, an miRNA–mRNA correlation analysis revealed at least one significant negative correlation between 15 of the identified miRNAs and a set of 50 artificial intelligence (AI)-selected genes, previously identified by us as relevant for TTFT prediction in the same cohort of CLL patients. In conclusion, the identification of specific miRNAs as predictors of TTFT holds promise for enhancing risk stratification in CLL to predict therapeutic needs. However, further validation studies and in-depth functional analyses are required to confirm the robustness of these observations and to facilitate their translation into meaningful clinical utility.

26 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ENEnnio Nano
Ennio Nano
FRFrancesco Reggiani
Francesco Reggiani
AAAdriana Agnese Amaro
Adriana Agnese Amaro
PMPaola Monti
Paola Monti
MCMonica Colombo
Monica Colombo
Giovanna CutronaGiovanna Cutrona
Giovanna Cutrona
A “watch and wait” strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study six well-established variables (i.e., Rai stage, beta-2-microglobulin levels, IGVH mutational status, del11q, del17p, and NOTCH1 mutations) maintained significant associations with TTFT in a basic multivariable model, collectively yielding a Harrell's C-index of 75% and explaining 45.4% of the variance in the prediction of TTFT. Concerning miRNAs, 73 out of 513 were significantly associated with TTFT in a univariable model; of these, 16 retained an in-dependent relationship with the outcome in a multivariable analysis. For 8 of these (i.e., miR-582-3p, miR-33a-3p, miR-516a-5p, miR-99a-5p, and miR-296-3p, miR-502-5p, miR-625-5p, and miR-29c-3p) a lower expression correlated with a shorter TTFT, whereas in the remaining eight (i.e., miR-150-5p, miR-148a-3p, miR-28-5p, miR-144-5p, miR-671-5p, miR-1-3p, miR-193a-3p, and miR-124-3p) the higher expression was associated with shorter TTFT. Integrating these miRNAs into the basic model significantly enhanced predictive accuracy, raising the Harrell’C index to 81.1% and the explained variation in TTFT to 63.3%. Moreover, the inclusion of the miRNA scores enhanced the Integrated Discrimination Improvement (IDI) and the Net Reclassification Index (NRI), underscoring the potential of miRNAs to refine CLL prognostic models and providing insights for clinical decision-making. In silico analyses on the differently expressed miRNAs revealed their potential regulatory functions of several pathways, including those involved in the therapeutic responses. To add a bio-logical context to the clinical evidence, a miRNA-mRNA correlation analysis revealed at least one significant negative correlation between 15 of the identified miRNAs and a set of 50 Artificial Intelligence (AI) selected genes, previously identified by us as relevant for TTFT prediction in the same cohort of CLL patients. In conclusion, the identification of specific miRNAs as predictors of TTFT holds promise for enhancing risk stratification in CLL to predict therapeutic needs. However, further validation studies and in-depth functional analyses are required to confirm the robustness of these observations and to facilitate their translation into meaningful clinical utility.

1 August 2023
Verified
Conference Paper
Open access
PDF file
CACarlo Adornetto
Carlo Adornetto
Gianluigi GrecoGianluigi Greco
Gianluigi Greco
Electronic proceedings of IJCAI 2023